Readoutin 14d
CanariaBio Inc. — Oregovomab
Phase 3 primary completion: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Carcinoma, Ovarian Epithelial